Drug Trial Radar · NCT03401320
Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)
Last checked: Nov 20, 2026Latest source record: Dec 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Nov 6, 2017
Primary completion
May 17, 2024
Study completion May 17, 2024
Sponsor
- Lead sponsor
- Rovi Pharmaceuticals LaboratoriesIndustry
- Sponsor type
- Industry
- First posted
- Jan 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I, open label, dose escalation study designed to evaluate the pharmacokinetics, safety, and tolerability of single intramuscular injections of Letrozole ISM® at different strengths in voluntary healthy post menopausal women
Conditions
- Healthy
Interventions
Letrozole ISMDrug
2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM
Primary outcomes
What the sponsor says the trial is designed to measure.
- λzTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
- CmaxTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
- Cmax/DTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
- tmaxTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
- tlagTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
- t½Time frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
- AUC∞Time frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
- AUC∞/DTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
- AUCextrapTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
- AUClastTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
- Vz/FTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
- CL/FTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational Site Number 42001
Prague, Czech Republic, Czechia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.